Azd9291 Osimertinib
Osimertinib mesylate powder, also known as AZD9291 or Osimertinib, belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which work by blocking the activity of mutated EGFR proteins, thereby Inhibit the growth and spread of diseased cells. It is often used in patients who have developed resistance to other EGFR inhibitors. It explicitly targets subsets of malignant cells with particular mutations in the EGFR gene, the epidermal growth factor receptor. It is classified as an inhibitor of tyrosine kinases, enzymes involved in the growth and division of diseased cells. With particular EGFR mutations, like the T790M mutation, frequently present in patients who have previously received treatment with other EGFR inhibitors, AZD9291 is selective for a subset of malignant cells. As a first line of treatment, the medicine is not advised for EGFR exon 19 deletions or exon 21 L858R mutations. It is commonly used as a second-line treatment for NSCLC, particularly in patients whose disease persists despite initial treatment with other EGFR inhibitors. If you have more questions about AZD9291 mesylate, please contact Xi'an Sonwu. Xi'an Sonwu can provide you with azd9291 mesylate powder.
Osimertinib Indication
1. First-line treatment
AZD9291 is approved as a first-line treatment for metastatic NSCLC with specific EGFR mutations. It targets two primary mutations: the exon 21 L858R mutation and the exon 19 deletions. These mutations are changes in the epidermal growth factor receptor (EGFR) gene, a key player in regulating cell growth and division. A population of NSCLC cells harboring these mutations are more sensitive to EGFR tyrosine kinase inhibitors (TKIs), making them a suitable target for it.
The approval of first-line therapy is a significant advance in the treatment of NSCLC. Clinical studies have shown that AZD9291, as a first-line treatment, has superior efficacy in terms of progression-free survival compared with older-generation EGFR TKIs (such as erlotinib or gefitinib). That makes it the first choice as initial systemic therapy for eligible patients with EGFR-mutated NSCLC.
2. Second-line treatment (after EGFR-TKI treatment)
Osimertinib plays a crucial role in second-line treatment, particularly in patients who have developed resistance to other EGFR inhibitors. After an initial positive response to first-generation EGFR TKIs such as erlotinib or gefitinib, some patients eventually develop resistance, often due to developing a secondary EGFR mutation known as T790M. The T790M mutation is a gatekeeper mutation that occurs in the ATP-binding pocket of the EGFR gene. It limits the effectiveness of first-generation EGFR TKIs, leading to disease progression. AZD9291 has demonstrated efficacy against bad cells harboring the T790M resistance mutation, making it a valuable option for patients with disease progression on prior EGFR TKI therapy.
3.T790M mutation detection
It must be validated that the T790M mutation exists before starting it as second-line therapy. That is typically accomplished by analyzing the genetic composition of the incorrect cell using a liquid biopsy or biopsy. Detecting this mutation is critical to identifying patients most likely to benefit from treatment with it.
What Is The Side Effects Of Osimertinib
AZD9291, like any medication, may cause side effects. It's crucial to remember that different people may suffer other side effects, and their severity may differ. Common side effects, as well as more serious ones, may occur.
Common Side Effects
1. Gastrointestinal Issues
Diarrhea
Nausea
2. Dermatological Effects
Rash
Dry skin
3. Respiratory Issues
Cough
4. Cardiovascular Effects
QT interval prolongation (affecting the heart's electrical activity; typically monitored through ECG)
5. Fatigue
Tiredness or weakness
6. Eye Disorders
inflammation of the outermost layer of the eye, known as conjunctivitis
Less Common But Potentially Serious Side Effects
1. Interstitial Lung Disease (ILD)
ILD is a rare but severe side effect that can cause difficulty breathing, cough, or fever. It's essential to report any new or worsening respiratory symptoms promptly.
2. Cardiac Issues
It can rarely cause cardiac events, and patients with a history of heart problems may be at an increased risk. Monitoring for signs of heart-related issues is essential.
3. Hepatotoxicity
Liver problems, including increased liver enzyme levels, have been reported. Generally speaking, routine liver function monitoring is advised.
4. Eye Disorders
More severe eye disorders, such as keratitis or corneal perforation, though rare, have been reported.
5. Electrolyte Imbalance
Changes in electrolyte levels, including decreased phosphate levels, have been observed.
Osimertinib With Or Without Chemotherapy In Egfr-Mutated Advanced Nsclc
First-line treatment
In first-line therapy, AZD9291 is effective in patients with advanced NSCLC harboring specific EGFR mutations (exon 19 deletion or exon 21 L858R mutation). Clinical trials such as the FLAURA trial have shown that it improves progression-free survival compared with traditional EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib or erlotinib. In this setting, it is generally considered the preferred first-line treatment option, particularly in patients with sensitizing EGFR mutations.
Combined with chemotherapy
Although it has shown efficacy as monotherapy, combination therapy may be considered in certain circumstances. For example, in some cases of advanced NSCLC with specific EGFR mutations, chemotherapy may be combined with it, mainly if the disease cell burden is high or there is concern about disease progression.
Sequential therapy
Patients may occasionally receive AZD9291 after chemotherapy. This approach may be considered in cases where EGFR mutation status becomes evident after initiation of chemotherapy or when it is introduced as second-line therapy. Sequential therapy aims to optimize treatment based on the evolving characteristics of the disease and the patient's response to treatment.
If you want to know the AZD9291 manufacturer, you can contact Xi'an Sonwu. Click the email, and then you get high-quality AZD9291.
Email: sales@sonwu.com